Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 inhibitor + bevacizumab + carboplatin + cisplatin + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy regimen that includes a PD-1 inhibitor (immune checkpoint inhibitor), bevacizumab (anti-VEGF monoclonal antibody), and chemotherapy agents (carboplatin, cisplatin, and pemetrexed). This combination approach targets multiple aspects of cancer biology: the PD-1 inhibitor reinvigorates T cell immune responses against tumors, bevacizumab inhibits angiogenesis by targeting VEGF, and the chemotherapy agents directly attack cancer cells through different mechanisms.
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on PD-1 inhibitor + bevacizumab + carboplatin + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 inhibitor + bevacizumab + carboplatin + cisplatin + pemetrexed.